

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED

阿里健康信息技術有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 00241)

CHANGE OF DIRECTORS AND CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board announces that Ms. ZHANG Yu has resigned as a non-executive Director, with effect from June 9, 2019.

The Board also announces that Mr. XU Hong has been appointed as a non-executive Director and Ms. HUANG Yi Fei, (Vanessa) has been appointed as an independent non-executive Director, the chairman of the Remuneration Committee, and a member of the Audit Committee, with effect from June 9, 2019.

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. ZHANG Yu (“**Ms. Zhang**”) has tendered her resignation as a non-executive Director with effect from June 9, 2019.

Ms. Zhang resigned to better focus on her other business engagements, and confirmed that she has no disagreement with the Board and there are no circumstances related to her resignation which need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company.

The Company would like to thank Ms. Zhang for all her past contributions to the Group.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. XU Hong (“**Mr. Xu**”) has been appointed as a non-executive Director with effect from June 9, 2019.

Mr. XU Hong, aged 46, was appointed as a non-executive Director on June 9, 2019. Mr. Xu is currently a vice president and special assistant to the chief executive officer of Alibaba Group Holding Limited, a director of DSM Grup Danışmanlık İletişim ve Satış Ticaret A.Ş., and a director of C2 Capital Partners GP Limited. He has also been a non-executive director of Lianhua Supermarket Holdings Co., Ltd. (聯華超市股份有限公司) (Stock code: 980), a company listed on the Main Board of the Stock Exchange since August 28, 2018, and a director of Suning Commerce Group Co., Ltd. (蘇寧雲商集團股份有限公司) (Stock code: 2024), a company listed on the Shenzhen Stock Exchange since May 8, 2019, respectively. Prior to joining Alibaba Group Holding Limited, Mr. Xu worked at PricewaterhouseCoopers and became a partner in July 2007. Mr. Xu obtained a Bachelor’s of Science Degree in Physics in July 1996 from Fudan University in the People’s Republic of China and he is a member of the Chinese Institute of Certified Public Accountants.

As at the date of this announcement, Mr. Xu is not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

Save as disclosed in this announcement, Mr. Xu did not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed in this announcement, Mr. Xu did not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years and did not hold any other position with the Company or other members of the Group.

Mr. Xu has entered into an appointment letter with the Company for a term of one year, which is renewable for a one-year period upon expiry of each term. He is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the bye-laws of the Company (the “**Bye-Laws**”) and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Mr. Xu does not receive any remuneration from the Group as a non-executive Director. Save as disclosed herein, Mr. Xu has confirmed that there is no other information that is required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to his appointment that needs to be brought to the attention of the shareholders of the Company.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board is pleased to announce that Ms. HUANG Yi Fei, (Vanessa) (“**Ms. Huang**”) has been appointed as an independent non-executive Director with effect from June 9, 2019.

Ms. HUANG Yi Fei, (Vanessa), aged 46, was appointed as an independent non-executive Director on June 9, 2019. Ms. Huang is currently a General Partner at BVCF Management. Ms. Huang has over 20 years of investment banking experience in the United States and Hong Kong. Prior to joining BVCF, she was Head of Emerging Asia Healthcare Investment Banking at J.P. Morgan. Before J.P. Morgan, she led Deutsche Bank Asia’s healthcare investment banking coverage. Ms. Huang gained biotech industry experience at Amgen. During her time in investment banking, Ms. Huang worked with companies and investors across Asia Pacific as well as global multinational companies and institutional investors. Her coverage included all subsectors of healthcare — pharmaceutical, biotech, medtech and services. She advised on multiple cross-border mergers and acquisitions and different stages of capital raising. Ms. Huang is a member of the Biotech Advisory Panel of the Stock Exchange and a member of the Admission Panel of the Incu-Bio Incubation Programme of the Hong Kong Science and Technology Parks Corporation. She is also co-Chairman of the Healthcare Committee of the Hong Kong Venture Capital and Private Equity Association. Ms. Huang obtained a Master of Science Degree in Engineering-Economic Systems from Stanford University in June 1996 and a Master of Business Administration from The Wharton School, University of Pennsylvania in June 2003, respectively.

As at the date of this announcement, Ms. Huang was not interested or deemed to be interested in any shares or underlying shares of the Company pursuant to Part XV of the SFO nor did she have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed herein, Ms. Huang did not hold any directorship in any other Hong Kong or overseas listed public companies in the last three years and did not hold any other position with the Company or other members of the Group.

Ms. Huang has entered into an appointment letter with the Company for a term of one year, which is renewable for a one-year period upon expiry of each term. She is subject to retirement by rotation and re-election at the annual general meetings of the Company in accordance with the Bye-Laws and the Listing Rules. Ms. Huang is entitled to receive a director’s fee of HKD316,800 per annum as an independent non-executive Director. Save as disclosed herein, Ms. Huang has confirmed that there is no other information that is required to be disclosed in accordance with Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter relating to her appointment that needs to be brought to the attention of the shareholders of the Company.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

The Board further announces that Ms. Huang Yi Fei, (Vanessa) has been appointed as the chairman of the remuneration committee of the Company (the “**Remuneration Committee**”) and a member of the audit committee of the Company (the “**Audit Committee**”), with effect from June 9, 2019.

The Board would like to congratulate Mr. Xu and Ms. Huang on their new appointments.

By Order of the Board
Alibaba Health Information Technology Limited
SHEN Difan
Chief Executive Officer and Executive Director

Hong Kong, June 9, 2019

As at the date of this announcement, the Board comprises eight directors, of which (i) two are executive Directors, namely Mr. SHEN Difan and Mr. WANG Qiang; (ii) three are non-executive Directors, namely Mr. WU Yongming, Mr. WANG Lei and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei, (Vanessa).